Drug Profile
Research programme: anticancer monoclonal antibodies - Meristem Therapeutics
Alternative Names: Monomeric IgA1; Monomeric IgA2; Monomeric IgA3Latest Information Update: 05 Mar 2013
Price :
$50
*
At a glance
- Originator Meristem Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Feb 2008 No development reported - Preclinical for Cancer in France (Parenteral)
- 24 Feb 2008 No development reported - Preclinical for Cancer in USA (Parenteral)
- 04 Mar 2005 Preclinical trials in Cancer in France (Parenteral)